(Q37776624)

23 August 2017

1 reference

title

Pathogenesis of Sjögren's syndrome and therapeutic consequences (English)

1 reference

23 August 2017

0 references

1 reference

Jacques-Eric Gottenberg

2

object named as

Jacques-Eric Gottenberg

0 references

Xavier Mariette

1

object named as

Xavier Mariette

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20671520

13 June 2024

publication date

1 September 2010

1 reference

full work available at URL

23 August 2017

https://journals.lww.com/10.1097/BOR.0b013e32833c36c5

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Current Opinion in Rheumatology

13 June 2024

published in

1 reference

23 August 2017

volume

22

1 reference

23 August 2017

issue

5

1 reference

23 August 2017

page(s)

471-477

1 reference

Pathogenesis of Sjögren's syndrome

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Genetics of systemic lupus erythematosus and Sjögren's syndrome

13 June 2024

2

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

An important role for B-cell activation factor and B cells in the pathogenesis of Sjögren's syndrome

13 June 2024

3

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

B cell depletion in lupus and Sjögren's syndrome: an update

13 June 2024

4

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism

13 June 2024

5

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects.

13 June 2024

6

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome

13 June 2024

7

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Peripheral blood gene expression profiling in Sjögren's syndrome

13 June 2024

8

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Association of an IRF5 gene functional polymorphism with Sjögren's syndrome

13 June 2024

9

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren's syndrome

13 June 2024

10

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

The CGGGG insertion/deletion polymorphism of theIRF5promoter is a strong risk factor for primary Sjögren's syndrome

13 June 2024

11

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Variant form of STAT4 is associated with primary Sjögren's syndrome

13 June 2024

12

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo.

13 June 2024

13

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Confirmation of an association between rs6822844 at the Il2-Il21 region and multiple autoimmune diseases: evidence of a general susceptibility locus

13 June 2024

14

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function

13 June 2024

15

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Decrease of blood dendritic cells and increase of tissue-infiltrating dendritic cells are involved in the induction of Sjögren's syndrome but not in the maintenance

13 June 2024

16

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Expression of the retinoblastoma protein RbAp48 in exocrine glands leads to Sjögren's syndrome-like autoimmune exocrinopathy

13 June 2024

17

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Functional estrogen receptors alpha and beta are expressed in normal human salivary gland epithelium and apparently mediate immunomodulatory effects

13 June 2024

18

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Detection of Epstein-Barr virus DNA by in Situ hybridization and polymerase chain reaction in salivary gland biopsy specimens from patients with Sjögren's syndrome

13 June 2024

19

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Possible involvement of EBV-mediated alpha-fodrin cleavage for organ-specific autoantigen in Sjogren's syndrome

13 June 2024

20

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3.

13 June 2024

21

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

13 June 2024

Cracking the BAFF code.

22

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome

13 June 2024

23

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus

13 June 2024

24

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome.

13 June 2024

25

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome

13 June 2024

26

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome

13 June 2024

27

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways

13 June 2024

28

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

B-cell-activating factor expressions in salivary epithelial cells after dsRNA virus infection depends on RNA-activated protein kinase activation

13 June 2024

29

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus

13 June 2024

30

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in humans and mice

13 June 2024

31

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis

13 June 2024

32

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Increased expression of interleukin-7 in labial salivary glands of patients with primary Sjögren's syndrome correlates with increased inflammation

13 June 2024

33

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

CXCL13, CCL21, and CXCL12 Expression in Salivary Glands of Patients with Sjogren's Syndrome and MALT Lymphoma: Association with Reactive and Malignant Areas of Lymphoid Organization

13 June 2024

34

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Sjögren's syndrome disease damage index and disease activity index: Scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients

13 June 2024

35

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Sjogren's Systemic Clinical Activity Index (SCAI) a systemic disease activity measure for use in clinical trials in primary Sjogren's syndrome

13 June 2024

36

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome

13 June 2024

37

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome

13 June 2024

38

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

13 June 2024

39

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data

13 June 2024

40

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

13 June 2024

41

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome

13 June 2024

42

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20)

13 June 2024

43

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.

13 June 2024

44

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.

13 June 2024

45

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

13 June 2024

46

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren's syndrome in salivary glands of non-obese diabetic mice

13 June 2024

47

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syndrome

13 June 2024

48

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome

13 June 2024

49

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome

13 June 2024

50

1 reference

https://api.crossref.org/works/10.1097/BOR.0B013E32833C36C5

13 June 2024

Identifiers

1 reference

23 August 2017

1 reference